Latest Insider Transactions at Y M Abs Therapeutics, Inc. (YMAB)
This section provides a real-time view of insider transactions for Y M Abs Therapeutics, Inc. (YMAB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Y-mAbs Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Y-mAbs Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 22
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.84%
|
$100,000
$25.94 P/Share
|
|
Oct 15
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.27%
|
$108,000
$27.2 P/Share
|
|
Oct 04
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.81%
|
$112,000
$28.78 P/Share
|
|
Sep 30
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.27%
|
$112,000
$28.26 P/Share
|
|
Sep 22
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.78%
|
$120,000
$30.82 P/Share
|
|
Sep 15
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.27%
|
$132,000
$33.64 P/Share
|
|
Sep 07
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.75%
|
$128,000
$32.03 P/Share
|
|
Sep 07
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$100,000
$2.0 P/Share
|
|
Sep 02
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
50,000
-3.22%
|
$1,650,000
$33.18 P/Share
|
|
Aug 23
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.72%
|
$112,000
$28.6 P/Share
|
|
Aug 17
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
1,779
-0.11%
|
$49,812
$28.96 P/Share
|
|
Aug 16
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
26,111
-0.83%
|
$757,219
$29.24 P/Share
|
|
Aug 13
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
1,110
-0.07%
|
$34,410
$31.01 P/Share
|
|
Aug 12
2021
|
Vignesh Rajah SVP & CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
1,374
+30.91%
|
$39,846
$29.95 P/Share
|
|
Aug 04
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.69%
|
$132,000
$33.72 P/Share
|
|
Aug 03
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$132,000
$33.73 P/Share
|
|
Jul 22
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.66%
|
$136,000
$34.5 P/Share
|
|
Jul 20
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$128,000
$32.47 P/Share
|
|
Jul 07
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$124,000
$31.87 P/Share
|
|
Jul 06
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.63%
|
$136,000
$34.15 P/Share
|
|
Jun 30
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$132,000
$33.86 P/Share
|
|
Jun 22
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.61%
|
$144,000
$36.17 P/Share
|
|
Jun 14
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$140,000
$35.8 P/Share
|
|
Jun 10
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
11,229
-0.27%
|
$404,244
$36.15 P/Share
|
|
Jun 10
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
11,229
-0.27%
|
$404,244
$36.15 P/Share
|
|
Jun 09
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
116,700
-2.71%
|
$4,201,200
$36.19 P/Share
|
|
Jun 09
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
116,700
-2.71%
|
$4,201,200
$36.19 P/Share
|
|
Jun 08
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
33,300
-0.77%
|
$1,165,500
$35.28 P/Share
|
|
Jun 08
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
33,300
-0.77%
|
$1,165,500
$35.28 P/Share
|
|
Jun 07
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
72,400
-1.64%
|
$2,461,600
$34.15 P/Share
|
|
Jun 07
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
72,400
-1.64%
|
$2,461,600
$34.15 P/Share
|
|
Jun 04
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.58%
|
$132,000
$33.48 P/Share
|
|
Jun 04
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
3,841
-0.09%
|
$130,594
$34.03 P/Share
|
|
Jun 04
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
3,841
-0.09%
|
$130,594
$34.03 P/Share
|
|
Jun 03
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
30,666
-0.69%
|
$1,011,978
$33.19 P/Share
|
|
Jun 03
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
30,666
-0.69%
|
$1,011,978
$33.19 P/Share
|
|
Jun 01
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
6,864
-0.15%
|
$240,240
$35.57 P/Share
|
|
Jun 01
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
6,864
-0.15%
|
$240,240
$35.57 P/Share
|
|
May 28
2021
|
Biotech Ap S Wg Director |
SELL
Open market or private sale
|
Direct |
25,000
-0.56%
|
$900,000
$36.34 P/Share
|
|
May 28
2021
|
Johan Wedell Wedellsborg Director |
SELL
Open market or private sale
|
Indirect |
25,000
-0.56%
|
$900,000
$36.34 P/Share
|
|
May 28
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$144,000
$36.95 P/Share
|
|
May 24
2021
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
4,000
-1.56%
|
$140,000
$35.61 P/Share
|
|
May 18
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$136,000
$34.07 P/Share
|
|
Apr 26
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$189,000
$27.96 P/Share
|
|
Apr 26
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$14,000
$2.0 P/Share
|
|
Apr 12
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
4,000
-0.25%
|
$104,000
$26.6 P/Share
|
|
Apr 12
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$182,000
$26.61 P/Share
|
|
Apr 12
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$14,000
$2.0 P/Share
|
|
Apr 01
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
6,000
-0.37%
|
$180,000
$30.27 P/Share
|
|
Apr 01
2021
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
9,000
-100.0%
|
$270,000
$30.26 P/Share
|